A Randomized Non-Inferiority Study of Mepi™ Press 2 vs UrgoK2® for Compression Therapy in Venous Leg Ulcers

ClinicalTrials.gov ID

NCT07600489

Lead Sponsor

Molnlycke Health Care ABINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

386Estimated

Last Update Posted

May 20, 2026Actual

Start Date

May 2026Estimated

Primary Completion Date

May 2028Estimated

Completion Date

May 2028Estimated

Official Title

A Comparative, Adaptive, Randomized, Non-Inferiority Clinical Investigation of Two-Layer Compression Bandages Mepi™ Press 2 Versus UrgoK2® in the Treatment of Venous Leg Ulcers

Brief Summary

Venous leg ulcers (VLUs) account for approximately 70% of all lower limb ulcers and affect an estimated 0.032% to 1% of the population in Western countries, corresponding to approximately 265,000 to 650,000 individuals in France. Effective management of VLUs is essential to reduce patient burden and associated healthcare costs. Compression therapy is the cornerstone of VLU treatment , as it improves venous return, reduces oedema, and promotes wound healing. Multilayer compression bandage systems, including two-layer systems, are considered the gold standard, and in France, they are recommended as first-line treatment for VLUs.

The goal of this clinical trial is to evaluate whether the Mepi™ Press 2 compression system is non-inferior to UrgoK2® in the treatment of venous leg ulcers in adult patients.

The main question it aims to answer is:

-Is Mepi™ Press 2 non-inferior to UrgoK2® in terms of the proportion of completely healed VLUs within 12 weeks?

Researchers will compare Mepi™ Press 2 with UrgoK2® to determine whether similar clinical efficacy, performance, and safety can be achieved.

Participants are adult patients with venous leg ulcers of less than 24 months duration requiring treatment with a two-layer compression bandage system. The study is multicenter, involving approximately 25 sites in France, and plans to enroll 386 participants.

Participants will:

• Receive compression therapy with either Mepi™ Press 2 or UrgoK2® in accordance with standard of care
• Receive an appropriate primary wound dressing prior to compression
• Attend up to five study visits over a period of up to 12 weeks (or until wound healing, whichever occurs first)
• Be assessed for wound healing, safety, and device performance throughout the study

• Venous Leg Ulcer (VLU)
• Compression Bandages

• Compression bandage system (Mepi™ Press 2)
• Compression bandage system (UrgoK2®)
• Wound Dressing Material

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients ≥ 18 years.
• Stage C6 venous leg ulcer diagnosed less than 24 months ago.
• 2cm² ≤ VLU surface area ≤ 40cm².
• ABPI equal or higher than 0.8 and equal or lower than 1.3.
• Able to read, understand and speak French for their medical care.
• Agreeing to follow the procedures described in the CIP.
• Benefiting from a social insurance coverage.

Exclusion Criteria:

• Any contraindication to investigational or comparator medical devices mentioned in their respective IFUs.
• Planned endovenous treatment or surgical venous stripping / exeresis within 8 weeks before planned inclusion date, or before end of participation to the study.
• Treatment with chemotherapy or antineoplastic agent within the last 6 months.
• Active wound infection or wound infection treatment within the past 4 weeks before inclusion or current use of silver dressings.
• Pregnant or breastfeeding women.
• Persons deprived from their liberty.
• Persons protected under guardianship or curatorship.
• Any person who, as per investigator's decision, is not suitable to participate in the investigation for any other reason.-

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Molnlycke Health Care ABINDUSTRY

Collaborators

Euraxi PharmaINDUSTRY

sblaise@chu-grenoble.fr+33 (0)4 76 76 75 75

centreplaieslyon@protonmail.com+33 4 49 44 00 90

judith.catella@chu-lyon.fr+33 4 72 11 80 88

cecile.durant@chu-nantes.fr+33 2 40 08 33 33

dr.kassab@pdp86.fr+33 5 49 61 70 00

malloizel-delaunay.j@chu-toulouse.fr+33 5 61 77 22 33

pleger@clinique-pasteur.com+33 5 62 21 31 31

• Evaluation of the Efficacy of Multilayer Compression & UrgoStart Plus

  NCT06007703

  CompletedObservationalUpdated Oct 3, 2025
• Efficacy and Safety of URGOBD001 Compression System

  NCT05158764

  CompletedInterventionalNot ApplicableUpdated Oct 17, 2023
• Efficacy and Safety of Light Compression System in the Local Treatment of Mixed Leg Ulcers (PROMETHEE Clinical Investigation)

  NCT06899919

  RecruitingInterventionalNot ApplicableUpdated Apr 8, 2025
• Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM)

  NCT04613687

  Unknown statusInterventionalNot ApplicableUpdated Nov 3, 2020
• VLU Non-Inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-Layer Bandaging

  NCT02680834

  TerminatedInterventionalNot ApplicableUpdated Feb 19, 2020
• Assessing Sensor-Guided Compression Therapy for Venous Leg Ulcers Healing Outcomes

  NCT07268482

  Not yet recruitingInterventionalNot ApplicableUpdated Dec 5, 2025